SCHEMBL11033766

SCHEMBL11033766

CN1CCN(c2ccc(Nc3cc(-c4ccccc4F)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 3/20 0.51
▸ INSR P06213 1/20 0.49
▸ ALK Q9UM73 1/20 0.49
▸ BTK Q06187 2/20 0.49
▸ FLT3 P36888 1/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ OPRM1 P35372 1/20 0.48
▸ OPRD1 P41143 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ CDK4 P11802 3/20 0.48
▸ CCND1 P24385 2/20 0.48
▸ CDK6 Q00534 2/20 0.48
▸ CCNT1 O60563 1/20 0.48
▸ CDK9 P50750 1/20 0.48
▸ CDK11A Q9UQ88 1/20 0.48
▸ JAK2 O60674 1/20 0.47
▸ JAK1 P23458 1/20 0.47
▸ TYK2 P29597 1/20 0.47
▸ JAK3 P52333 1/20 0.47
▸ MAPKAPK2 P49137 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11028611 0.89 SLC2A1 (0.51) SLC2A1INSRALKCDK4CCND1
SCHEMBL11031519 0.88 SLC2A1 (0.57) SLC2A1INSRALKCDK4CCND1
SCHEMBL11029599 0.88 MAPKAPK2 (0.58) SLC2A1INSRALKBTKCDK4
SCHEMBL11026741 0.87 FYN (0.55) SLC2A1BTKCDK4CCND1CDK6
SCHEMBL27922264 0.87 SLC2A1 (0.49) SLC2A1INSRALKBTKFLT3
SCHEMBL11033969 0.86 SLC2A1 (0.56) SLC2A1INSRALKCDK4CDK6
SCHEMBL11028125 0.85 ALK (0.56) SLC2A1INSRALKFLT3CDK4
SCHEMBL11029346 0.83 MAPKAPK2 (0.61) SLC2A1INSRALKBTKFLT3
SCHEMBL11031445 0.83 SLC2A1 (0.51) SLC2A1BTKCDK4CCND1CDK6
SCHEMBL11033167 0.83 BTK (0.48) SLC2A1INSRALKBTKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885INSR 689/4885ALK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback